Atrial fibrillation patients saw 69% lower risk with common blood thinners
60-Word AI Digest
Direct oral anticoagulants cut the risk of serious clinical events by 69% in atrial fibrillation patients with an intermediate risk of stroke, according to the randomized SINGLE-AF trial. The benefit was driven mainly by fewer ischemic strokes, with no increase in major bleeding.
Key Takeaways
- Direct oral anticoagulants cut the risk of serious clinical events by 69% in atrial fibrillation patients with an intermediate risk of stroke, according to the randomized SINGLE-AF trial.
- The benefit was driven mainly by fewer ischemic strokes, with no increase in major bleeding.
- Full details and original dispatch available below.
Direct oral anticoagulants cut the risk of serious clinical events by 69% in atrial fibrillation patients with an intermediate risk of stroke, according to the randomized SINGLE-AF trial. The benefit was driven mainly by fewer ischemic strokes, with no increase in major bleeding.
Original Publisher Attribution
This summary was curated from ScienceDaily.